Centre Hospitalier Universitaire Vaudois
chuv.chTotal trials
202
Active
39
Phase 3
5
Total enrollment
13,360,162
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 26 of 26 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dosage Adjustment Rules for Augmented Renal Clearance (DAR-ARC) for piperacillin-tazobactam and meropenem | — | — | — | — | — | 1 | |
| Standard dosages of piperacillin-tazobactam or meropenem | — | — | — | — | — | 1 | |
| Immunonutrition | — | — | — | — | — | 1 | |
| bevacizumab | — | — | — | — | — | 2 | |
| Patent blue V dye | — | — | — | — | — | 1 | |
| Indocyanine green dye | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Pembrolizumab - additional treatment | — | — | — | — | — | 1 | |
| Sodium lactate | — | — | — | — | — | 1 | |
| Apixaban 5 MG [Eliquis] | — | — | — | — | — | 1 | |
| Edoxaban 60 MG [Lixiana] | — | — | — | — | — | 1 | |
| Trimipramine | — | — | — | — | — | 1 | |
| Cohort 1: Atezolizumab | — | — | — | — | — | 1 | |
| Cohort 2: Atezolizumab | — | — | — | — | — | 1 | |
| Cohort 2: Bevacizumab | — | — | — | — | — | 1 | |
| CMP-001 | — | — | — | — | — | 1 | |
| Autologous dendritic cell vaccine loaded with personalized peptides | — | — | — | — | — | 2 | |
| Low dose cyclophosphamide | — | — | — | — | 2 | ||
| Cyclophosphamide | — | — | — | — | — | 3 | |
| Fludarabine | — | — | — | — | — | 3 | |
| Interleukin-2 | — | — | — | — | — | 3 | |
| NY-ESO-1 TCR redirected autologous T cell product | — | — | — | — | — | 1 | |
| Non-myeloablative lymphodepleting chemotherapy | — | — | — | — | — | 1 | |
| NeoTIL | — | — | — | — | — | 1 | |
| Pericapsular nerve group (PENG) block with 0.75% ropivacaine guided by ultrasound | — | — | — | — | — | 1 | |
| Femoral, sciatic and lateral femoral cutaneous nerve block with 0.375% ropivacaine | — | — | — | — | — | 1 |
Next readouts
- 2025-12
- 2026-03
- 2026-06
- 2026-06-01
- 2026-08
- 2027-03
- 2027-06
- 2027-09-01
- 2027-11
- 2028-01
Top conditions
- Postoperative Pain5
- Analgesia5
- Melanoma4
- Posttraumatic Stress Disorder4
- Obstructive Sleep Apnea4
- End Stage Renal Disease4
- Surgery3
- Ischemic Stroke3
Frequently asked questions about Centre Hospitalier Universitaire Vaudois
- How many clinical trials does Centre Hospitalier Universitaire Vaudois have on ClinicalTrials.gov?
- Centre Hospitalier Universitaire Vaudois is listed as the lead sponsor on 202 clinical trials in ClinicalTrials.gov, 39 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centre Hospitalier Universitaire Vaudois's trials are in Phase 3?
- 5 of Centre Hospitalier Universitaire Vaudois's trials are in Phase 3, spread across 26 active drug programs.
- What therapeutic areas does Centre Hospitalier Universitaire Vaudois focus on?
- Centre Hospitalier Universitaire Vaudois's most-studied conditions on ClinicalTrials.gov are Postoperative Pain, Analgesia, Melanoma, Posttraumatic Stress Disorder, Obstructive Sleep Apnea.
- When are Centre Hospitalier Universitaire Vaudois's next clinical trial readouts?
- Centre Hospitalier Universitaire Vaudois has 10 upcoming primary-completion readouts tracked here; the soonest is “CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)”, expected around 2025-12.